Additionally, increased PRDX1 expression was correlated with TP53 mutations and was associated with worse clinical outcomes in AML patients (Fig. 3B, C), suggesting a potential role for PRDX1 in disease progression and treatment resistance. Here, PRDX1 is linked to acute myeloid leukemia.